-+ 0.00%
-+ 0.00%
-+ 0.00%

What Does SELLAS Life Sciences Group (SLS) Phase 3 AML Success Change Now?

Simply Wall St·11/18/2026 09:11:56
Listen to the news
  • SELLAS Life Sciences Group (NasdaqCM:SLS) reported that its Phase 3 REGAL trial of galinpepimut S in AML met the primary overall survival endpoint.
  • The REGAL study showed a statistically and clinically significant survival benefit with a meaningful reduction in risk of death and no new safety issues.
  • The company plans to submit a Biologics License Application to the FDA for GPS in AML and is seeking accelerated review.
  • The GPS Phase 3 REGAL survival result could reshape SELLAS Life Sciences Group, but other factors still deserve close attention. Our analysis turns up 3 warning signs (3 major) for SELLAS Life Sciences Group as well.

For investors tracking how late stage oncology stories intersect with broader market themes, the same questions now apply across 42 profitable AI stocks that aren't just burning cash.

NasdaqCM:SLS 1-Year Stock Price Chart
NasdaqCM:SLS 1-Year Stock Price Chart

SELLAS Life Sciences Group, a US based late stage oncology developer, focuses on cancer therapeutics where late line patients often have few options. A positive Phase 3 outcome in acute myeloid leukemia places the business directly in the front line of high risk, high impact biotech drug development.

See which insiders are buying and selling SELLAS Life Sciences Group following this latest news.

How big is the REGAL survival signal for SELLAS Life Sciences Group?

The REGAL trial showed a median overall survival of 24.0 months for GPS versus 14.7 months for best available treatment, with a 41% reduction in risk of death and p=0.035. For a late line AML maintenance setting where options are limited, that kind of separation is a clear clinical signal investors will focus on.

Does this change the SELLAS Life Sciences Group Narrative?

The Simply Wall St Narrative had REGAL overall survival as the key catalyst supporting projected revenue growth, high forecast margins and heavy use of equity financing. Hitting the primary endpoint aligns with that thesis but does not remove other flagged risks such as dilution, legal investigations around REGAL disclosures and the 3D Medicines arbitration.

See how these catalysts shape SELLAS Life Sciences Group's path to a $32.50 fair value.

What should investors watch next to see if this momentum holds?

The immediate markers are SELLAS Life Sciences Group's upcoming FDA interactions and the planned Biologics License Application submission for GPS in the first half of 2027. Progress updates on the BLA timetable, the depth of the full REGAL dataset at a major conference and the market’s reception to the US$150m equity raise will indicate how durable sentiment is.

One big question on SELLAS Life Sciences Group that this article has not touched

Short term headlines rarely capture where detailed projections say a business could be a few years from now. SELLAS Life Sciences Group is no exception. See where analysts expect SELLAS Life Sciences Group to be in a few years.